Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:49-52. doi: 10.1111/jdv.17732.
Cutaneous squamous cell carcinoma (CSCC) is the most frequent post-transplant tumour entity resulting from immunosuppression treatment that is needed to prevent organ rejection. Solid organ transplant (SOT) recipients are at higher risk for CSCC and vulnerable for aggressive disease or a fatal course. Here, we report on a case of post-kidney transplant metastatic CSCC, demonstrating efficacy of cemiplimab in achieving complete remission after previous disease progression under cetuximab treatment. Unfortunately, the patient developed severe pneumonia, which was only later diagnosed as cemiplimab-associated pneumonitis. Due to a rapidly evolving septic condition, intensive care treatment was required and resulted in a fatal outcome. The patient's transplant remained intact, yet first-line treatment of advanced CSCC, such as with cemiplimab, should be weighed critically in SOT recipients, as transplant rejection may occur. However, the present case underlines the feasibility of cemiplimab as a second-line treatment option in this patient collective.
皮肤鳞状细胞癌（CSCC）是最常见的移植后肿瘤实体，是预防器官排斥所需的免疫抑制治疗的结果。实体器官移植（SOT）受者发生 CSCC 的风险更高，并且容易发生侵袭性疾病或致命病程。在这里，我们报告了一例肾移植后转移性 CSCC 病例，该病例在先前接受西妥昔单抗治疗后疾病进展的情况下，使用西妥昔单抗治疗后达到完全缓解。不幸的是，该患者发生严重肺炎，直到后来才被诊断为西妥昔单抗相关肺炎。由于迅速发展为脓毒症，需要重症监护治疗，导致最终死亡。患者的移植器官仍然完整，但在 SOT 受者中应慎重考虑西妥昔单抗等晚期 CSCC 的一线治疗，因为可能会发生移植排斥。然而，本病例强调了西妥昔单抗作为该患者群体二线治疗选择的可行性。
